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| INTRODUCTION
Malignant melanoma is a tumor arising from melanocytes located in the skin or mucous membranes. Although melanoma represents a limited number of cutaneous cancers each year, it remains a significant public health crisis because the metastatic disease is associated with poor survival. The incidence of the disease has doubled since 1973 and the median age at diagnosis is 40, making it one of the most significant cancers responsible for productive years of life lost. In 2017, it is estimated that there will be 87,110 new cases of melanoma in the United States and 9,730 deaths from the disease (American Cancer Society-Facts & Figures, 2017) . There has been major progress in the treatment of advanced melanoma, largely through advances in understanding how to manipulate immune responses and target selective genetic mutations in patients with melanoma. While immunotherapy is characterized by induction of durable responses in a limited number of patients, targeted therapy has been characterized by high response rates but nearly universal emergence of drug resistance, usually within several months (Merlino et al., 2016) . The V600E activating mutation of BRAF (MAPK pathway effector) renders this kinase constitutively active in 45% of cutaneous melanomas, and inhibitors of BRAF, MEK, or both have revolutionized the treatment of BRAF-mutated melanoma patients (Merlino et al., 2016; Miller, Flaherty, & Tsao, 2014) .
The mechanisms of drug resistance are being identified, and strategies to circumvent therapy failure are urgently needed.
There is emerging evidence that in the context of acquired resistance, tumor cells will develop mechanisms that not only promote resistance to BRAF V600E-targeted therapy but also increase invasiveness favorable to further dissemination and metastasis. As we will illustrate later, the molecular effectors involved in resistance to BRAF V600E-targeted therapy are often playing key roles in melanoma cell motility and invasiveness. Therefore, resistance is often coupled to the development of an aggressive tumor phenotype, characterized by an active EMT-like process, increased motility, and invasion. In this review, we will focus on the transcription factors and coactivators playing an active role in resistance to BRAF V600E-targeted therapy, through a large variety of mechanisms. In addition to promoting adaptive or acquired resistance, the expression levels of some of these transcription factors, such as MITF (microphthalmia-associated transcription factor), favor a state of innate resistance in the context of melanoma cells harboring BRAF V600E mutations. 
| MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR: A COMPLEX RELATIONSHIP WITH RESISTANCE
A large body of evidence has designated microphthalmia-associated transcription factor (MITF) as a driver of melanoma progression (Hartman & Czyz, 2015) . However, the relationship between MITF expression level and resistance to BRAF inhibition appears to be complex and melanoma cell context-dependent. In addition, tumor heterogeneity regarding MITF expression level represents an intriguing feature of BRAF inhibitor-resistant melanomas.
| High and/or low levels of MITF and innate/ acquired resistance to BRAF inhibitors: limits of in vitro studies
Several studies performed in cellular systems found apparently conflicting results about the modulations of MITF associated with the mechanism of resistance to BRAF inhibition, as illustrated by the following studies described in this section. MITF was identified as one of the transcription factors activated downstream of the MAP kinase and cAMP pathways, whose expression conferred resistance to PLX4720, a potent and selective inhibitor of BRAF V600E (also called vemurafenib) (Johannessen et al., 2013) . It is conceivable that the increased expression of MITF (a target of ERK) in some BRAF V600E-resistant melanoma cells occurs to counteract a compromised ERK-mediated MITF activation. In addition, forced MITF overexpression rendered the WM266.4, SKMEL19, and UACC62 (BRAF V600E positive) melanoma cells resistant to PLX4720 (Van Allen et al., 2014) . In contrast, MITF loss has also been associated with resistance to BRAF inhibitors (BRAFi) . MITF loss at the transcriptional level occurs in four of seven melanoma cell lines, which have acquired in vitro resistance to the BRAF inhibitor PLX4720 (Muller et al., 2014 ). An independent study performed in two independent melanoma cell lines, SKMEL28 and MGH-CH1, also showed that the emergence of vemurafenib resistance was correlated with MITF loss (Ji et al., 2015) . Furthermore, low MITF levels and innate resistance to BRAFi have also been associated.
To determine the impact of endogenous MITF levels on intrinsic resistance to BRAF inhibition, treatment-naïve BRAF mutant melanoma cells were grouped based on their endogenous MITF expression and treated with PLX4720 for 6 days. A clear survival benefit was observed for the melanoma cell lines expressing low endogenous MITF as compared with those exhibiting high MITF expression (Muller et al., 2014) . In addition, a MITF-low/NFκB-high transcriptional signature was correlated with intrinsic resistance to PLX4720 (Konieczkowski et al., 2014) .
These in vitro studies altogether are indicative of the implication of MITF in resistance to BRAFi in a context-dependent manner, in relationship with the genetic/epigenetic background, the melanoma stage, or the differentiation level of the melanoma cell lines. However, its real contribution in the process of resistance has legitimately been addressed in the context of human tumors, which are by essence heterogeneous, as discussed below in 2.3.
| Impact of MITF modulations on receptor tyrosine kinase expression and/or activation
Receptor tyrosine kinases (RTKs) represent one important link between transcription factors and resistance to BRAF V600E-targeted therapy. In that section, we will give three examples for which this link has been investigated. One such RTK, AXL, is activated in melanomas (Tworkoski et al., 2011) and engaged in an autocrine loop due to endogenous production of its ligand Gas6 (Sensi et al., 2011) . In addition, AXL promotes pro-migratory and pro-invasive behavior (Sensi et al., 2011; Tworkoski et al., 2011) and resistance to the BRAF V600E inhibitor, PLX4720, in melanoma cells (Johannessen et al., 2010; Konieczkowski et al., 2014) . Overexpression of AXL in three melanoma cells lines, A375, SKMEL-28, and UACC-62, was sufficient to confer resistance to PLX4720 (Konieczkowski et al., 2014) .
Reinforcing these findings, Muller et al. (2014) demonstrated that the increased resistance to BRAF inhibition in melanoma cells expressing low levels of MITF was also associated with high levels of AXL, and showed a reverse correlation between MITF and receptor tyrosine kinases, including AXL (Muller et al., 2014) . This study confirmed previous studies showing a negative correlation between MITF and AXL in melanoma cells (Kim, Leung, Baguley, & Finlay, 2013; Sensi et al., 2011) . As loss of MITF (Carreira et al., 2006; Muller et al., 2014) and high AXL expression (Sensi et al., 2011; Tworkoski et al., 2011) are also accompanied by increased invasiveness, it suggests that the molecular events promoting increased invasiveness are linked to those involved in resistance to BRAF V600E-targeted therapy. A more recent study showed that ATF4, a key transcriptional mediator of the integrated stress response, decreased MITF transcription in melanoma cells, thereby contributing to the MITF-low/AXL-high gene expression program (Falletta et al., 2017) .
A second example of the impact of MITF loss on RTK activation is illustrated by the link MITF/EGFR. The emergence of vemurafenib resistance in the two melanoma cell lines, SKMEL28 and MGH-CH1, was correlated with MITF loss, in association with EGFR activation (Ji et al., 2015) . Further exploring this association, the investigatiors demonstrated that MITF suppression increased the expression of heparin-binding EGF (HB-EGF) and transforming growth factor-α, two EGFR ligands. Therefore, MITF suppression promotes autocrine signaling through EGFR activation to mediate resistance (Ji et al., 2015) .
The third example involves the RTK MET. The authors (Webster et al., 2014) were interested in the mechanism of innate drug resistance mediated by upregulation of the MET receptor. This study identified a melanoma lineage-specific enhancer, 63 kb downstream from the MET transcriptional start site, which displays inducible chromatin looping with the MET promoter to upregulate MET expression upon BRAF inhibition. Targeted genomic deletion (<7 bp) of the MITF motif within the MET enhancer suppressed inducible chromatin looping and innate drug resistance (Webster et al., 2014) .
| MITF modulations and resistance to BRAFi through the lens of tumor heterogeneity
In favor of the clinical relevance of MITF upregulation in the development of resistance to BRAFi, one study performed whole-exon sequencing of BRAF V600-mutant melanoma tissues obtained before treatment and after the development of resistance to the BRAF inhibitors vemurafenib and dabrafenib and identified a relapse-associated focal amplification of MITF in one patient (Van Allen et al., 2014) . In addition, the expression of the anti-apoptotic BCL2 family member, BCL2A1, which is a direct transcriptional target of MITF, is associated with poorer clinical responses to BRAF pathway inhibitors in melanoma patients (Haq et al., 2013) .
Apparently in contradiction to the aforementioned studies, one study showed that relapse specimens had lower MITF and higher EGFR levels as compared with the pretreatment melanoma samples in 3/3 pairs of vemurafenib-treated patients with BRAF V600-mutated melanomas (Ji et al., 2015) . To address the clinical relevance of the relationship between innate resistance to BRAFi and MITF/AXL levels, biopsies samples from patients with metastatic BRAF V600E melanoma were stratified into MITF-high/AXL-low and MITF-low/AXL-high on the basis of immunohistochemistry. Importantly, progression-free survival following dabrafenib/trametinib therapy was significantly shorter in the MITF-low/AXL-high group relative to the MITF-high/AXL-low group (median 5.0 months versus 14.5 months) (Konieczkowski et al., 2014) .
These studies may appear contradictory until we consider the complexity of the resistance mechanisms encountered in the clinic.
Tumor heterogeneity, in relationship with MITF levels, brings new light toward a more thorough understanding of these resistance mechanisms. Further delineating this tumor heterogeneity, Chapman and coll. (Chapman et al., 2014) (Chapman et al., 2014) and implicitly during the development of resistance to targeted therapy (Muller et al., 2014) .
Indeed, samples from patients before treatment with vemurafenib and matched vemurafenib-resistant tumors (after relapse) were analyzed by immunohistochemical staining. The analysis showed that melanoma resistance to BRAF inhibition in vivo is associated not only with increased MITF expression but also with its loss, even in different relapsed tumor clones from the same patient (Muller et al., 2014) .
Furthermore, melanoma cell clusters circulating in patient blood were shown heterogeneous in MITF expression level (Khoja et al., 2014) .
These results altogether suggest that tumor heterogeneity regarding MITF levels and the pro-invasive ability of tumor cells exist both in treatment-naïve progressing tumors and in BRAFi-resistant tumors.
Strengthening further this hypothesis, single-cell RNA sequencing
showed that malignant cells within the same treatment-naïve tumor displayed transcriptional heterogeneity associated with a drug resistance program. Tumors characterized by high levels of MITF also contained cells with a low level of MITF and elevated levels of AXL (Tirosh et al., 2016) .
| FOXDUPREGULATION: AN ADAPTIVE RESPONSE TO BRAF INHIBITORS
Mutant BRAF signaling represses the expression of FOXD3 in human melanoma cells in a MEK activity-dependent manner (Abel & Aplin, 2010) . The transcription factor FOXD3 was increased in melanoma cell lines treated with PLX4720 (Abel et al., 2013; Basile, Abel, & Aplin, 2012) , and siRNA-mediated FOXD3 depletion rendered melanoma cells sensitive to PLX4720 and PLX4032-induced cell death. In contrast, induced expression of FOXD3 provided protection against PLX4720-provoked cell death. These results suggested that FOXD3 upregulation promotes resistance to BRAF inhibitors (Basile et al., 2012) . Interestingly, Abel et al. (2013) reported FOXD3 upregulation as early as two hours after PLX4032 treatment, and up until 16 hours. FOXD3 upregulation and subsequent FOXD3-mediated upregulation of ERBB3 are described as an adaptive response to RAF inhibitors. This early, adaptive response would presumably promote a state of drug resistance, providing a time window for secondary genetic events that set the stage for permanent/acquired resistance (Abel et al., 2013; Basile et al., 2012) .
In favor of this hypothesis, melanoma cells initially depleted of FOXD3, exhibited a decreased ability to establish long-term resistance to PLX4720 (Basile et al., 2012) .
| RUNX2: A NEW PLAYER IN MELANOMA PROGRESSION AND ACQUIRED RESISTANCE TO BRAFI
RUNX2 was initially described as one of the transcription factors whose expression was significantly correlated with elevated levels of the non-canonical signaling member of the WNT family, WNT5A, following chronic treatment (over 10 weeks) with the BRAF inhibitors PLX4720 and PLX4032 (Anastas et al., 2014) . We previously demonstrated that RUNX2-deficient melanoma cells displayed a significant decrease in four receptor tyrosine kinases, EGFR, IGF-1R, PDGFRβ, and AXL, and strongly suggested a role for RUNX2 as a key player in mediating intrinsic RTK-associated pro-oncogenic properties in melanoma. In addition, we showed a dramatic upregulation of RUNX2 expression with concomitant upregulation of EGFR, IGF-1R, and AXL in melanoma cells rendered resistant to PLX4720 (Boregowda et al., 2016) . We then reported that PLX4720-resistant cells developed in an in vivo context exhibit an increase in RUNX2 levels when re-exposed to PLX4720 in vitro.
These findings suggest that RUNX2 might be involved in acquired resistance to PLX4720. To address the relevance of these findings in human melanoma, patient data from a cohort containing samples from untreated tumors and tumors treated with vemurafenib and dabrafenib, respectively , were analyzed. Probes for all three main RUNX2 transcripts were represented on the array. The expression of RUNX2 isoform 3 was significantly higher in vemurafenib-treated patients compared to the untreated group.
These results showing the upregulation of RUNX2 in melanoma lesions from patients treated with vemurafenib suggest that chronic exposure to BRAFi (PLX4720/vemurafenib) may favor RUNX2 upregulation and subsequent RTK upregulation, an important player in acquired resistance to these drugs (Boregowda et al., 2016) .
The mechanism(s) leading to RUNX2 upregulation in BRAFiresistant melanoma cells have yet to be discovered. One possible mechanism would involve WNT5A and the WNT5A-mediated activation of the PI3K/AKT pathway (Anastas et al., 2014) . As RUNX2 expression is increased by the PI3K/AKT pathway signaling (Boregowda et al., 2016; Cohen-Solal, Boregowda, & Lasfar, 2015) , elevated WNT5A expression and subsequent AKT pathway activation could result in RUNX2 overexpression. Therefore, any kinase rewiring that leads to hyperactivated PI3K/AKT signaling in melanomas resistant to BRAFi (Paraiso et al., 2011) would provide a favorable context for high RUNX2 expression.
| SRY (SEX-DETERMINING REGION Y)-BOX 10 (SOX10) REVERSIBLE SUPPRESSION IN BRAFI-RESISTANT CELLS
To determine the mechanism underlying increased EGFR expression in relapsed melanomas as compared with pretreatment tumors in 6 of 16 melanoma patients, Sun et al. (2014) (Sun et al., 2014) . In SKMEL28 and WM3248 melanoma cells, the acquisition of vemurafenib resistance was also associated with diminished expression of SOX10 (Ji et al., 2015; Kim et al., 2016) . The demonstration that SOX10 knockdown results in the activation of EGFR, PDGFRβ, and ERBB3 suggests that SOX10 decrease in vemurafenib-resistant melanoma cells positively affects not only expression of the RTKs but also their activation level (Sun et al., 2014) .
| THE STAT3-PAX3 AXIS
The introduction of the BRAF V600E mutation into immortalized melanocytes (hTERT/CDK4(R24C)/p53DD) (Garraway et al., 2005) results in STAT3 activation (as measured by expression of phospho-STAT3 (Tyr705) and phosphoSTAT3 (Ser727)) and upregulation of PAX3, a direct STAT3 transcriptional target (Hartman & Czyz, 2015) .
In the A375 and UACC62 human melanoma cells resistant to vemurafenib, higher concentrations of vemurafenib were required to inhibit the expression of phosphoSTAT3 (Tyr705) Altogether, these results indicate that the PAX3-STAT3 axis represents a target for overcoming acquired resistance to vemurafenib in melanoma cells. In favor of this hypothesis, combination therapy with WP1066, a small molecule targeting STAT3, and vemurafenib was able to overcome the acquired resistance to vemurafenib (Liu et al., 2013 ).
Similarly to MITF, a context-dependent relationship with resistance may apply to PAX3. PAX3 expression was decreased in SKMEL28 human melanoma cells resistant to vemurafenib (Ji et al., 2015) . In contrast to melanocytes, melanoma cells exhibit a negative PAX3-dependent regulation of MITF expression (Hartman & Czyz, 2015) .
Therefore, the context-dependent increase or decrease in PAX3 expression may play a role in the aforementioned context-dependent variation of MITF levels during the establishment of BRAFi resistance.
| THE BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR: A NEW PLAYER IN MELANOMA
The role of the bromodomain PHD finger transcription factor (BPTF)
in melanoma progression and in resistance to BRAF V600E-targeted therapy resides in BPTF ability to transcriptionally activate ERK expression in melanoma cells (Dar et al., 2015) . 1205LU melanoma cells exhibiting BPTF knockdown were 2.8-and 2.9-fold more sensitive to vemurafenib and dabrafenib than controls, respectively. In contrast, BPTF overexpression in those melanoma cells decreased sensitivity to vemurafenib or dabrafenib. Importantly, in six of eight patients progressing on BRAF inhibition, tumors exhibited marked heterogeneity in BPTF expression, whereas all tumors harvested before therapy had homogenous low BPTF staining, suggesting that increased levels of BPTF can mediate acquired resistance to BRAF inhibition. In addition, heterogeneity in BPTF expression and copy number indicates that there is a differential response to treatment within the tumor. This study suggests BPTF targeting as a possible approach to overcome resistance to BRAF inhibition (Dar et al., 2015) using bromodomain inhibitors targeting the bromodomain and extraterminal (BET) protein family (Filippakopoulos et al., 2010) or more specific BPTF bromodomain inhibitors.
| THE CAMP RESPONSE ELEMENT BINDING PROTEIN (CREB)
By expressing more than 15,000 genes individually in a BRAF V600 melanoma cell line (A375) treated with RAF, MEK, and ERK inhibi- In addition, the promoters of 19 resistance genes identified in this study carried CREB-responsive elements, including those of the transcription factors MITF, FOS, and NR4A2 (nuclear receptor subfamily 4 group A member 2) (Johannessen et al., 2013) . In the context of BRAF V600E inhibition preventing ERK-mediated MITF activation, the GPCR-mediated activation of CREB would increase MITF expression, thereby partially overcoming MITF impaired activation.
In an independent study, another mechanism of CREB activation in the context of resistance was described. PLX4032-resistant melanoma cells exhibited higher levels of phosphorylated CREB (S133) and higher CREB transcriptional activity than the sensitive parental cells (Hu et al., 2013) . CREB phosphorylation in those resistant cells was shown to result from PI3K/AKT activation (Hu et al., 2013) , in accordance with the PI3K/AKT pathway promoting CREB phosphorylation on serine 133 (Du & Montminy, 1998) . Treatment of the parental melanoma cells with PLX4032 resulted in a progressive increase in pAKT (S473) and pCREB (S133) levels within 36 hours (Hu et al., 2013) . These findings suggest that activation of PI3K/AKT and subsequent activation of CREB may occur early during the process of acquired resistance, although pCREB levels are maintained high once the resistance is established.
Further in vivo studies showed that xenografts from Mel-CV
PLX4032-resistant melanoma cells (Mel-CVR) treated with PLX4032
exhibited almost no response to the treatment as compared with xenografts derived from the parental cells Mel-CV. However, when CREB was knocked down in the Mel-CVR cells, the xenografts showed similar rates of regression as Mel-CV tumors in response to PLX4032, indicating that CREB plays a role in antagonizing PLX4032-mediated inhibition of melanoma growth in vivo (Hu et al., 2013) .
Collectively, these results suggest that CREB may be phosphorylated and activated in melanoma cells resistant to BRAF V600E inhibitors through a GPCR/cAMP/PKA axis or the PI3K/AKT pathway. For the second mechanism, the increase in pAKT (S473) occurring within hours of PLX4032 treatment would suggest that inhibition of ERK phosphorylation by PLX4032 or other BRAF V600E inhibitors could promote a positive feedback on AKT activity. This is in accordance with the reported cross-inhibition between the RAS-ERK and PI3K/AKT pathways (Mendoza, Er, & Blenis, 2011) . When constitutive ERK phosphorylation is blocked by BRAF V600E inhibitors, it releases the crossinhibition and activates the PI3K/AKT pathway, setting up the stage for adaptive mechanisms leading to more sustained acquired resistance.
| YAP/TAZ ACTIVATION AND ACTIN REMODELING
Lin and coll. (Lin et al., 2015) aimed to identify genes that, when silenced, enhanced the response to the BRAF inhibitor vemurafenib, and screened 27,500 shRNA targeting 5,046 signaling components for this purpose. LGX818 and MEK162). Melanoma patients who had a complete response to therapy exhibited lower YAP expression in the pretreatment tumor samples, while patients who had an incomplete response to therapy showed higher YAP levels in the baseline tumor samples.
Finally, this study found increased YAP levels in each paired tumor obtained after acquired resistance in comparison with the matched pretreatment specimen. These results suggest that increased YAP expression might limit the clinical efficacy of BRAF (and MEK inhibitors) (Lin et al., 2015) .
Furthermore, two types of studies suggested that YAP and its paralogue TAZ (transcriptional coactivator with PDZ-binding motifs) could be a link between actin remodeling and vemurafenib resistance. First, earlier studies had identified actin cytoskeletal structure and tension as upstream regulators of YAP/TAZ activity (Dupont et al., 2011; Zhao et al., 2012) . Second, substantial increases in basal actin stress fiber formation were described in both SKMEL28 and WM3248 human melanoma cell lines resistant to vemurafenib (Kim et al., 2016) . In favor of a role of YAP/TAZ in mediating resistance, the latter study demonstrated that YAP/TAZ nuclear localization and transcriptional activation of YAP/TAZ target genes were increased in vemurafenib-resistant cells. By performing double knockdown of YAP and TAZ, they further showed that vemurafenibresistant cells were highly dependent of YAP/TAZ activity for both survival and proliferation (Kim et al., 2016) . In addition, parental SKMEL28 and WM3248 cells expressing constitutively active YAP-5SA (containing five serine-to-alanine substitution which prevents its phosphorylation and cytoplasmic retention) acquired resistance to vemurafenib treatment. Finally, using cytochalasin D, an inhibitor of actin polymerization, and blebbistatin, to block actomyosin contraction, they demonstrated that an increase in both actin stress fibers and cytoskeletal tension is a key inducer of YAP/TAZ nuclear localization and activation in vemurafenib-resistant melanoma cells, and that those two processes mediate YAP/TAZ-dependent vemurafenib resistance (Kim et al., 2016) .
| THE TRANSCRIPTION FACTORS GLI1 AND GLI2 AND THE NON-CANONICAL TGFΒ SIGNALING
GLI1 and GLI2 are transcription factors downstream of the hedgehog (Hh) signaling pathway. However, they can also be activated by non-canonical Hh pathways, including the TGFβ/SMAD pathway (Dennler, Andre, Verrecchia, & Mauviel, 2009) . A recent study showed that the expression of GLI1 (8/9 melanoma cell lines) and to a lesser extent GLI2 (4/9 melanoma cell lines) was increased in vemurafenib- 
| OTHER TRANSCRIPTION FACTORS DYSREGULATED DURING THE PROCESS OF RESISTANCE TO BRAF V600E INHIBITION
Transcription factors represent a class of highly dysregulated cellular effectors in BRAF V600E-carrying melanoma cells resistant to BRAF inhibition. The following studies further underscore the wide diversity of mechanisms contributing to the development of resistance to BRAF inhibition.
| Upregulation of ERK-regulated transcription factors
Several ERK-regulated transcription factors, such as FOS, JUNB, ETS2, and ETV1, were identified in systematic gain of function resistance studies designed to identify genes whose upregulation confers resistance to MAPK pathway inhibition. These resistance mechanisms favor the overexpression of a transcription factor whose activity is inhibited as a result of ERK inhibition by BRAFi (Johannessen et al., 2013) . CREB is also a target of ERK, and its expression is increased in relapsing tumors (Johannessen et al., 2013) .
Similarly, MITF (another target of ERK) is increased in some BRAF V600E-resistant melanoma cells to counteract a deficit in ERKmediated activation (Johannessen et al., 2013; Van Allen et al., 2014) .
| The adipocyte enhancer-binding protein 1 upregulation protects ERK from inactivation
Adipocyte enhancer-binding protein 1 (AEBP1) was identified as a transcriptional repressor. In addition, AEBP1 directly interacts with ERK and specifically modulates ERK activation by protecting it from its phosphatase DUSP6. This role of AEBP1 is independent of its transcriptional function (Kim, Muise, Lyons, & Ro, 2001) . In light of these findings, the report that AEBP1 is a PLX4032 resistance-associated gene strengthens the link between AEBP1 and ERK activity (Hu et al., 2013) . AEBP1 is upregulated in PLX4032-resistant melanoma cells downstream of the PI3K/AKT/CREB axis via CREB-mediated transcriptional regulation. In addition, the report shows that the development of BRAF inhibitor resistance in the clinic (PLX4032 or dabrafenib) is closely associated with AEBP1 upregulation in a subgroup of BRAF V600E melanomas (Hu et al., 2013) . We can envision that in the context of inhibition of ERK phosphorylation with BRAF V600E inhibitors, the remaining ERK phosphorylation may be maintained by AEBP1-mediated protection from DUSP6. Furthermore, AEBP1 is the downstream effector of CREB, which promotes NFκB activation, through hyperactivation of the PI3K/AKT/CREB/AEBP1 pathway in PLX4032-resistant melanoma cells.
| Upregulation of EMT-and phenotype switching-related transcription factors
SOX9 (a RUNX2 target gene) and TWIST2 were among the transcription factors whose expression was significantly correlated with elevated levels of WNT5A, following chronic treatment (over 10 weeks) with the BRAF inhibitors PLX4720 and PLX4032 (Anastas et al., 2014) . The three transcription factors RUNX2, SOX9, and TWIST2 are involved in the EMT process (Cohen-Solal et al., 2015) , finding that reinforces the hypothesis of an association between resistance to BRAFi and selection of a melanoma population with increased invasiveness.
The phenotype switching in melanoma is similar to the epithelial to mesenchymal transition (EMT) process, associated with the progression of epithelial tumors to metastatic disease. Interestingly, an established microenvironment, consisting of aged fibroblasts, promoted phenotype switching in melanoma cells in favor of increased invasion and decreased proliferation (Kaur et al., 2016) . Growing evidence points to phenotype switching as a major mechanism mediating resistance to BRAF V600E-targeted therapy (Kemper, De Goeje, Peeper, & Van Amerongen, 2014) . The phenotype switching involves transcription factors such as ZEB2, ZEB1, TWIST, SLUG, MITF, c-JUN, and STAT3 (Hoek et al., 2008; Li, Dhillon, Anderson, Mcarthur, & Ferrao, 2015; Ramsdale et al., 2015; Richard et al., 2016) ; some of them demonstrated key players in resistance to BRAF inhibition (Menon et al., 2013) .
| Transcription regulators of glycolysis and resistance to BRAFi
Transcriptional regulators of glycolysis have also been implicated in the response of melanoma cells to BRAF inhibition. Vemurafenib treatment decreased the expression of the transcription factors MYC and HIF-1α at the mRNA and protein levels in BRAF V600E melanoma cell lines. In addition, altered expression of MYC and HIF-1α
(the key mediator of hypoxia-stimulated gene transcription) in clinical melanoma specimens after BRAFi treatment was reported (Parmenter et al., 2014) . These two transcription factors are established positive regulators of glucose metabolism (Dang, 2012; Marin-Hernandez, Gallardo-Perez, Ralph, Rodriguez-Enriquez, & Moreno-Sanchez, 2009) and were shown to promote glucose uptake in BRAF V600E melanoma cells (Parmenter et al., 2014) . Suppression of glycolysis and cell proliferation by vemurafenib was partially reversed by the expression of inducible c-MYC or by exposure to hypoxia (causing HIF-1α stabilization) (Parmenter et al., 2014) . Interestingly, RUNX2 physically and functionally interacts with HIF1-α (Kwon et al., 2011; Lee et al., 2012) and RUNX2 stabilizes HIF1-α under normoxic conditions (Lee et al., 2012) . As mentioned earlier, RUNX2 overexpression in melanoma has been associated with acquired resistance to BRAFi (Anastas et al., 2014; Boregowda et al., 2016) . Therefore, in addition to increasing RTK expression and promoting migration and invasion (Boregowda et al., 2016) , another mechanism through which RUNX2 might promote resistance would involve HIF-1α stabilization.
| INTERPLAY TUMOR MICROENVIRONMENT AND MELANOMA CELLS: ROLE OF TRANSCRIPTION FACTORS

| Stromal cells contribute to transcription factors dysregulation and resistance to BRAFi
Cross talk between the tumor microenvironment and melanoma cells is also critical for vemurafenib resistance (Menon & Schaider, 2015; Straussman et al., 2012) . Extrinsic factors from the microenvironment contribute to BRAFi resistance in part through the secretion of hepatocyte growth factor (HGF) by stromal cells, particularly fibroblasts (Straussman et al., 2012) , after vemurafenib treatment (Fedorenko, Wargo, Flaherty, Messina, & Smalley, 2015) . It is therefore expected that activation of the MAPK and PI3K/AKT pathways by HGF-mediated MET activation in melanoma cells will induce the expression of ERKregulated transcription factors such as FOS, JUNB, ETS2, and ETV1, and of AKT-regulated transcription factors such as CREB or RUNX2, all involved in resistance to BRAFi. In addition, Kaur and colleagues (Kaur et al., 2016 ) described a new mechanism where aged fibroblasts secrete a WNT pathway antagonist, sFRP2, which leads to a decrease in MITF and β-catenin, whose loss has also been shown to contribute to resistance to vemurafenib (Biechele et al., 2012; Kaur et al., 2016) .
| Immune microenvironment and resistance to BRAF inhibition
The role of the immune microenvironment in resistance was illustrated by the identification of macrophage-derived TNFα as a crucial melanoma growth factor promoting resistance to MAPK pathway inhibitors through an increase in MITF expression. The study showed that TNFα regulates MITF expression through the canonical NFκB signaling in BRAF V600 melanoma cells lines (Smith et al., 2014) . characterized by increased expression of c-JUN, driving adaptive phenotypic plasticity (Ramsdale et al., 2015) . Although the authors did not investigate the upstream regulators of c-JUN in the tumor microenvironment, it is conceivable that the pro-inflammatory environment of BRAFi-treated melanomas (Young et al., 2017) 
